Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

HR-positive/HER2-positive; Biomarkers; Gene expression profiling

Detalles Bibliográficos
Autores: PERNAS SIMON, SONIA, Pascual, Tomás, Villacampa Javierre, Guillermo, Oliveira, Mafalda, Escriva de Romani, Santiago, Paré, Laia, Nuciforo, Paolo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/14011
Acceso en línea:http://hdl.handle.net/11351/14011
Access Level:acceso abierto
Palabra clave:Metàstasi
Mama - Càncer - Tractament
Quimioteràpia combinada
Marcadors tumorals
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
id ES_8a868e957c97b55ea2af00a42c2df44b
oai_identifier_str oai:recercat.cat:11351/14011
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
title Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
spellingShingle Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
PERNAS SIMON, SONIA
Metàstasi
Mama - Càncer - Tractament
Quimioteràpia combinada
Marcadors tumorals
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
title_short Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
title_full Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
title_fullStr Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
title_full_unstemmed Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
title_sort Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
dc.creator.none.fl_str_mv PERNAS SIMON, SONIA
Pascual, Tomás
Villacampa Javierre, Guillermo
Oliveira, Mafalda
Escriva de Romani, Santiago
Paré, Laia
Nuciforo, Paolo
author PERNAS SIMON, SONIA
author_facet PERNAS SIMON, SONIA
Pascual, Tomás
Villacampa Javierre, Guillermo
Oliveira, Mafalda
Escriva de Romani, Santiago
Paré, Laia
Nuciforo, Paolo
author_role author
author2 Pascual, Tomás
Villacampa Javierre, Guillermo
Oliveira, Mafalda
Escriva de Romani, Santiago
Paré, Laia
Nuciforo, Paolo
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Pascual T] SOLTI Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Medicine Department, University of Barcelona, Barcelona, Spain. [Villacampa G] SOLTI Cancer Research Group, Barcelona, Spain. Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Oliveira M, Escrivá-de-Romaní S] SOLTI Cancer Research Group, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pernas S] SOLTI Cancer Research Group, Barcelona, Spain. Institut Catala d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain. [Paré L] SOLTI Cancer Research Group, Barcelona, Spain. Reveal Genomics, Barcelona, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Metàstasi
Mama - Càncer - Tractament
Quimioteràpia combinada
Marcadors tumorals
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
topic Metàstasi
Mama - Càncer - Tractament
Quimioteràpia combinada
Marcadors tumorals
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, Tumor
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumorales
description HR-positive/HER2-positive; Biomarkers; Gene expression profiling
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11351/14011
http://hdl.handle.net/11351/14011
url http://hdl.handle.net/11351/14011
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv ESMO Open;10(9)
https://doi.org/10.1016/j.esmoop.2025.105572
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412723201146880
spelling Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trialPERNAS SIMON, SONIAPascual, TomásVillacampa Javierre, GuillermoOliveira, MafaldaEscriva de Romani, SantiagoParé, LaiaNuciforo, PaoloMetàstasiMama - Càncer - TractamentQuimioteràpia combinadaMarcadors tumoralsDISEASES::Neoplasms::Neoplasms by Site::Breast NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy ProtocolsDISEASES::Neoplasms::Neoplastic Processes::Neoplasm MetastasisCHEMICALS AND DRUGS::Biological Factors::Biomarkers::Biomarkers, TumorENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mamaOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinadaENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásicaCOMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::marcadores tumoralesHR-positive/HER2-positive; Biomarkers; Gene expression profilingHR-positiu/HER2-positiu; Biomarcadors; Perfils d'expressió gènicaHR-positivo/HER2-positivo; Biomarcadores; Perfil de expresión génicaBackground The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This manuscript presents final overall survival (OS) results and biomarker analyses. Patients and methods Patients previously treated with trastuzumab and two to four regimens were eligible. For estrogen receptor (ER)-negative disease (cohort A), patients received palbociclib and trastuzumab. For ER-positive disease, patients were randomized 1 : 1 to cohort B1 (no additional therapy) or B2 (letrozole). OS and long-term progression-free survival (PFS) were pre-defined secondary endpoints. Kaplan–Meier curves and stratified Cox models were used. Results Among 71 patients, median OS was 29.8 months [95% confidence interval (CI) 20.9-38.0 months]; 4-year OS rates were 13.3% (A), 35.7% (B1), and 32.3% (B2). PAM50 luminal subtypes showed better OS than non-luminal subtypes (38.0 versus 26.6 months). Exploratory biomarker analyses found luminal-related genes associated with better long-term survival, while basal and proliferation-related genes were linked to resistance. Higher luminal A, luminal B, and previously reported chemo-endocrine scores correlated with favorable prognoses. Conclusions These findings highlight the relevance of gene expression profiling in HER2-positive breast cancer and support biomarker-driven patient selection. Long-term PATRICIA results validate the potential of non-chemotherapy-based approaches in HR-positive/HER2-positive MBC.This work was supported by a grant from Pfizer (no grant number), which also provided palbociclib. Pfizer had no role in the management of this trial. All decisions and responsibilities for the trial were managed solely by the sponsor, the SOLTI Group.ElsevierInstitut Català de la Salut[Pascual T] SOLTI Cancer Research Group, Barcelona, Spain. Department of Medical Oncology, Cancer Institute and Blood Disorders, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Medicine Department, University of Barcelona, Barcelona, Spain. [Villacampa G] SOLTI Cancer Research Group, Barcelona, Spain. Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Oliveira M, Escrivá-de-Romaní S] SOLTI Cancer Research Group, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pernas S] SOLTI Cancer Research Group, Barcelona, Spain. Institut Catala d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain. [Paré L] SOLTI Cancer Research Group, Barcelona, Spain. Reveal Genomics, Barcelona, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/11351/14011http://hdl.handle.net/11351/14011Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésESMO Open;10(9)https://doi.org/10.1016/j.esmoop.2025.105572Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/140112026-05-29T05:05:01Z
score 15,811543

Similares en LA Referencia